@article{MRA, author = {Jozef Oweis and Sandra Adams}, title = { Dispelling Myths and Misconceptions about Chronic Obstructive Pulmonary Disease}, journal = {Medical Research Archives}, volume = {12}, number = {7}, year = {2024}, keywords = {}, abstract = {Introduction: Chronic obstructive pulmonary disease is one of the major causes of disability and mortality in the world. Despite better efforts to understand this disease, there are still multiple misconceptions regarding the evaluation and management of these complex patients. Purpose: The purpose of this review article is to utilize four hypothetical patient case presentations to dispel common myths regarding the evaluation and management of patients with chronic obstructive pulmonary disease.  Hypothetical Case Presentations: Natasha, Kevin, Joe and Mary are hypothetical patients with chronic obstructive pulmonary disease, whose cases were developed based on clinical experiences and a literature review in order to discredit common myths and misconceptions among clinicians and patients. Common Myths and Misconceptions: Four common myths and misconceptions about patients with chronic obstructive pulmonary disease include: myth #1 symptoms of dyspnea are always reported, myth #2 prolonged cough following an upper respiratory infection is trivial, myth #3 therapy with inhaled corticosteroid plus a long-acting beta 2 agonist is ideal for all newly diagnosed patients, and myth #4 all patients with chronic obstructive pulmonary disease have exacerbations without serious consequences. Throughout this article, we will apply the 2024 Global initiative for chronic Obstructive Lung Disease recommendations to these hypothetical patients to debunk each of these myths and misconceptions.   Conclusions and Clinical Implications: Throughout this article, we have applied information from the literature and 2024 Global initiative for chronic Obstructive Lung Disease report to dispel common myths and misconceptions. The reality is that symptoms of chronic obstructive pulmonary disease are variable and not all patients report dyspnea. In addition, initial therapy should include dual long-acting bronchodilator therapy, but inhaled corticosteroids may be added in specific situations, such as patients with documented eosinophilia. Finally, acute exacerbations of this disease often have serious consequences and should be methodically prevented and aggressively treated.}, issn = {2375-1924}, doi = {10.18103/mra.v12i7.5463}, url = {https://esmed.org/MRA/mra/article/view/5463} }